Plain language summary
======================

**Why was the study done?** Cycle ergometer training (CET) and inspiratory muscle training (IMT) -- the two pulmonary rehabilitation methods have been shown to benefit patients with COPD. But the additional benefit of IMT when given as an adjunct to CET remains unclear.

**What did the researchers do and find?** We enrolled and divided 81 COPD patients into three groups: the combined training group received 8 weeks CET + IMT; the CET training group received 8 weeks CET; the control group received 8 weeks free walking. Then we took a comprehensive approach in evaluating the effects of these training sessions. We found that CET + IMT was more effective than CET alone in increasing inspiratory strength, but not the other aspects. Patients with weakened respiratory muscles in the combined training group derived similar effects to those without respiratory muscle weakness after training. Patients with malnutrition and normal nutrition shared the same effects after rehabilitation.

**What do these results mean?** CET + IMT offers modest benefit compared with cycle ergometer alone except in increasing inspiratory muscle strength. Combined training may not bring additional effects in patients with weakened inspiratory muscles. Nutritional status had slight impact on pulmonary rehabilitation.

Introduction
============

COPD is a common and complicated airway disorder which has become the fourth leading cause of death worldwide. The multi-system involvement of COPD may result in impaired exercise capacity, poor health-related quality of life, and mental problems, including depression and anxiety.[@b1-copd-12-2655]--[@b4-copd-12-2655] For COPD patients, pulmonary rehabilitation has been shown to improve symptoms, exercise tolerance, and well-being. Among diverse approaches to pulmonary rehabilitation, cycle ergometer training (CET) may optimally enhance the quadriceps muscle functions, significantly improve exercise performance, dyspnea, and quality of life, and therefore has been accepted as an important part of pulmonary rehabilitation.[@b4-copd-12-2655] Apart from CET, studies also confirmed that inspiratory muscle training (IMT) may increase inspiratory muscle strength and reduce the severity of dyspnea in COPD patients.[@b5-copd-12-2655],[@b6-copd-12-2655] Despite the beneficial effects of IMT on inspiratory muscle strength and endurance, its additional benefits on exercise performance and quality of life did not seem to be significant.[@b7-copd-12-2655] As such, future studies in COPD patients should focus specifically on the effect of IMT or IMT + other rehabilitative interventions compared to other IMT-excluded rehabilitations for outcome assessments. Unfortunately, due to the limited sample sizes and mixed conclusions of previous studies, the benefit of IMT in pulmonary rehabilitation when given as an adjunct to CET remains unclear.[@b7-copd-12-2655]--[@b11-copd-12-2655] Furthermore, in these published studies, a comprehensive outcome assessment approach for the combined training has rarely been performed, which should ideally account for more parameters such as fat-free mass index (FFMI), body mass index (BMI), airflow obstruction, dyspnea, and exercise capacity index (BODE), depression and anxiety, COPD Assessment Test (CAT), modified Medical Research Council (mMRC), and St George's Respiratory Questionnaire (SGRQ) rather than merely focus on the resultant benefits for muscle function and exercise endurance. In light of the reference to pulmonary rehabilitation as a comprehensive intervention by the American Thoracic Society/European Respiratory Society (ATS/ERS 2013) statement,[@b4-copd-12-2655] we speculated that a comprehensive approach would be much more worthwhile when evaluating the effects of rehabilitation in COPD patients.

Given that both CET and IMT may be therapeutically beneficial for post-clinical COPD patients in whom damage to the quadriceps muscles and inspiratory muscles is associated with poor exercise performance and life quality,[@b12-copd-12-2655] we hypothesized that a combination of the two may improve the outcome of pulmonary rehabilitation. The aim of this study was to comprehensively evaluate whether CET + IMT would lead to additional benefits compared with CET alone in COPD patients. In addition, the effect of pulmonary rehabilitation was compared between patients with and without respiratory muscle weakness.

Materials and methods
=====================

Study design
------------

This was a prospective randomized controlled study conducted in a rehabilitation center at Zhujiang Hospital affiliated to Southern Medical University (Guangzhou, China) between April 1, 2015 and October 1, 2015. Reporting of this study was in accordance with the Consolidated Standard of Reporting Trials (CONSORT) statement.[@b13-copd-12-2655] The study protocol rigorously followed the Declaration of Helsinki and Committee on Publication Ethics (COPE) guidelines, and was approved by the Ethics Committee of Zhujiang Hospital, Southern Medical University. All participants in this study signed a written informed consent. Prior to the start of this trial, the study protocol was registered online (register [ClinicalTrials.gov](http://ClinicalTrials.gov), number: NCT02285400).

Recruitment of patients
-----------------------

The inclusion criteria were: age \>40 years; diagnosis of stable COPD based on the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines;[@b1-copd-12-2655] and no participation in any pulmonary rehabilitation program in the previous 2 months. To be included in this study, the participants had to be able to understand the investigator's instructions and complete the tests required in the study. Patients were excluded if they had acute or chronic airway diseases other than COPD, cardiovascular disorders (such as acute coronary syndrome), metabolic conditions (such as diabetes or hyperthyroidism), or other health problems that would interfere with exercise performance or the testing procedures.

Potentially eligible patients were recruited from the outpatient clinic of Southern Medical University Zhujiang Hospital. They were informed about the aim and procedure of this study. Within a half-year run-in period, we approached 261 consecutive patients with COPD, of whom 121 met our inclusion criteria and all were instructed to do a 30-minute free walk on the exercise area of our rehabilitation center three times weekly. During this period, the patients were allowed to quit and exit the study. Regular medication for COPD based on GOLD guidelines was also allowed during this period and throughout the study. At the end of the run-in period, 81 eligible patients remaining on free walk (16 females and 65 males; mean age 70.32±5.878 years) were enrolled in the trial. These 81 patients were randomized into three groups (CET + IMT group, CET group, and control group) using computer-generated random numbers at a 1:1:1 allocation ratio. The randomization and allocation was completed independently by a research nurse according to a random number sealed in opaque envelopes.

Study interventions
-------------------

The CET group received 8 weeks of CET alone, and the combined training group received 8 weeks of CET + IMT. The control group received 8 weeks of free walking as in the run-in period. All training was performed under the supervision of an experienced respiratory therapist. Throughout the study period, these subjects were on a standardized diet as prepared and guided by a designated dietitian according to the previous nutritional statement.[@b14-copd-12-2655]

Patients in the CET group received 30-minute CET three times per week for 8 weeks. The CET was performed on an electromechanically braked cycle (model E100 P/K, Cosmed, Rome, Italy) in our rehabilitation center. The exercise intensity threshold in the lower limbs was calculated as 70% maximal oxygen consumption (VO~2max~) during cardiopulmonary exercise testing (CPET). Interval training protocol was used whereby patients performed three workout sets, each 10 minutes in duration and separated by 3- to 5-minute rest intervals of unloaded cycling.[@b15-copd-12-2655] The training workload was evaluated weekly. We selected loads that patients described as "somewhat hard", ie, graded 12--14 on the Rating of Perceived Exertion (RPE) scale.[@b16-copd-12-2655]

Patients in the combined training group received 30-minute CET and 14-minute IMT three times per week for 8 weeks. The training sessions were separated such that the patients performed CET first as described previously, and then IMT after a 30-minute rest period from the end of CET. The IMT was given with a threshold-loaded IMT device (model HS730, Philips, Amsterdam, the Netherlands). Training was initiated at an intensity that was 30% of maximal inspiratory pressure (PI~max~) and had been tested with a digital manometer. Interval training protocol was used whereby patients performed seven workout sets, each 2 minutes in duration, separated by rest intervals lasting 1 minute.[@b5-copd-12-2655] The training load was adjusted weekly: the load was increased while maintaining an RPE grade of 12--14.

Patients in the control group completed a 30-minute free walk three times per week on the playground of the rehabilitation center, for 8 more weeks. As in the run-in period, there was no requirement for speed and distance. The patients were free to stop for a while if they felt uncomfortable due to dyspnea or fatigue, and go on walking when the symptoms subsided.

The severity of dyspnea was evaluated during exercise using the Borg scale.[@b17-copd-12-2655] Before the exercises, the Borg scale was explained to patients. To ensure patient safety and to guide the adjustment of training load, we monitored the following indicators during the training sessions to make sure that they were within permissible ranges: heart rate (HR) \< maximum HR obtained by CPET or 90% of predicted maximum (calculated as 90% × \[220 -- age in years\]); pulse oxygen saturation (SPO~2~) ≥85%; blood pressure (BP) ≤200/100 mmHg; Borg scale ≤5; RPE grade \<15 (tired). When any of these indicators exceeded the permissible range, the training session was suspended immediately, and the patient was instructed to have a rest and further evaluated by a physician for the need to terminate the training of the day or receive medications before proceeding with training.

Outcome measures
----------------

A comprehensive assessment of pulmonary rehabilitation was performed based on respiratory muscle strength, exercise capacity, pulmonary function, symptoms, nutritional status, mental status, and quality of life, using a number of measures closely relevant to COPD as described in the following paragraphs. The primary outcome measures were respiratory muscle strength and exercise capacity. The secondary outcome measures were pulmonary function, symptoms, nutritional status, mental status, and quality of life. All tests were conducted by an experienced respiratory therapist who was blinded to the study protocol. All these data were measured or recorded prior to the start (baseline) and within 2 days after the end of the study intervention.

### Respiratory muscle strength

Respiratory muscle strength was determined according to PI~max~ and maximal expiratory pressure (PE~max~) using a digital manometer (AZ-8205; AZ Instruments, Taichung City, Taiwan). The testing procedures were performed in adherence with the ATS/ERS standardization protocols.[@b18-copd-12-2655] Both PI~max~ and PE~max~ were measured at least three times, and the highest result was used for analysis. The testing error was required to be less than 20% and the interval between two consequent measurements was no less than 30 seconds. The lower limit of normal value for PI~max~ was 60 cmH~2~O.

### Exercise capacity

Exercise capacity was evaluated using the 6-minute walk test (6MWT) and a maximal exercise test. The 6MWT was performed for 30 m on a flat surface.[@b19-copd-12-2655] Oxyhemoglobin saturation and HR were monitored by pulse oximetry. The largest values measured over 2 days were chosen for analysis. Oxygen saturation was maintained at more than 90% during testing in all subjects. The patients used the Borg scale to rate dyspnea at the end of the 6MWT.

The maximal exercise test was evaluated the next day after 6MWT. The maximal exercise test was measured during standard 5 W/minute or 10 W/minute incremental symptom-limited cycle ergometer testing protocol using a CPET machine (Quark-PFT Ergo, Cosmed).[@b20-copd-12-2655] The protocol included three stages comprising: a rest stage (5 minutes of warming-up with a zero workload); an exercise stage (according to the exercise capacity of each patient to ensure the rate of workload progression, using a ramp protocol to increase the workload, keeping at 55--65 rpm until maximal exertion); and a recovery stage (3--5 minutes of recovery at zero workload). The measured CPET parameters included oxygen uptake (VO~2~), carbon dioxide output (VCO~2~), respiratory exchange ratio (RER), SPO~2~, and HR, as well as ventilatory pattern parameters including minute ventilation (VE), respiratory frequency (Rf), and tidal volume (VT). These parameters were measured at the following time points: at rest before beginning exercise; at the end of warm-up stage; at the anaerobic threshold (AT); at the peak. The patients used the Borg scale to rate dyspnea every minute. Progressive incremental exercise testing was ended when the following situation was shown in the patients: chest pain suggestive of ischemia; SPO~2~ ≤80% accompanied by symptoms and signs of severe hypoxemia; notable ischemic electrocardiogram changes and arrhythmia; fall in systolic pressure \>20 mmHg from the highest value during the test; or hypertension (\>250 mmHg systolic; \>120 mmHg diastolic).[@b20-copd-12-2655]

### Pulmonary function

Pulmonary function was measured using a spirometer (Pony FX229, Cosmed), which was calibrated daily, and in accordance with the ATS guidelines.[@b21-copd-12-2655] All baseline functional measures (including forced expiratory volume in 1 second \[FEV~1~\], FEV~1~ percent predicted \[%pred\], forced vital capacity \[FVC\], FVC %pred, FEV~1~/FVC, maximal voluntary ventilation \[MVV\], and inspiratory capacity \[IC\]) were recorded before and after a bronchodilator test. All lung function parameters were compared with the reference values published by the European Community for Steel and Coal.[@b22-copd-12-2655]

### Dyspnea, quality of life, and depression and anxiety

The severity of dyspnea was evaluated using the mMRC and the CAT.[@b23-copd-12-2655],[@b24-copd-12-2655] Quality of life was evaluated using the SGRQ.[@b25-copd-12-2655] Depression and anxiety were evaluated using the Hospital Anxiety and Depression Scale (HADS), which includes 14 questions (seven for depression and seven for anxiety).[@b26-copd-12-2655] All questionnaires were administered by an experienced investigator.

### Nutritional status

Nutritional status was measured using the BMI (calculated as body mass/height[@b2-copd-12-2655]) and FFMI (calculated as fat-free mass/height[@b2-copd-12-2655]). FFMI was measured twice by multifrequency and 8-spot electrodes, and the average value was chosen for analysis. We defined a low FFMI as being ≤16 kg/m^2^ in men and ≤15 kg/m^2^ in women.[@b27-copd-12-2655],[@b28-copd-12-2655]

Statistical analysis
====================

An intention-to-treat protocol was used for data analysis. For the primary analyses, we used the last observation carried forward (LOCF) imputation method for data of the drop-outs. The statistical analyses were performed using Statistical Package for the Social Sciences version 19.0 software (IBM Corporation, Armonk, NY, USA). Patient characteristics at baseline, shown in [Table 1](#t1-copd-12-2655){ref-type="table"}, were presented as mean ± SD. The values in other tables and figures were described as mean ± SE. The baseline differences between groups were compared using one-way analysis of variance (ANOVA). Based on general linear models, we used analysis of covariance models (ANCOVA) to analyze the difference of primary and secondary outcomes (after minus before intervention, shown as Δ), adjusting the models with least-significant difference (LSD) correction for the baseline score. We used a repeated measures ANOVA to compare the changes of ventilatory pattern parameters and Borg scores measured during CPET between groups as shown in [Figure 1](#f1-copd-12-2655){ref-type="fig"}. Subgroup analyses were also performed using ANCOVA with LSD adjustment. A *P*-value \<0.05 was considered statistically significant. We performed a sensitivity analysis with the same result.

Results
=======

Of the 81 patients initially included in the study, not all completed the whole training program. The number of dropouts was similar in the three training groups. Dropouts were due to: lost to follow-up (one from each group), refusal to continue the intervention (one from each group), and worsening of COPD (one each in the CET group and combined training group). Despite these dropouts, with an intention-to-treat analysis and the LOCF imputation method, our analysis accounted for all the 81 participants in this study coming from the control group (n=26), CET group (n=27), and the combined training group (n=28) ([Figure 2](#f2-copd-12-2655){ref-type="fig"}). The baseline characteristics of the patients were comparable among the three groups, as summarized in [Table 1](#t1-copd-12-2655){ref-type="table"}. For patients who remained throughout the study, all training sessions were completed as scheduled, and none of the daily training sessions was terminated due to patient discomfort, dyspnea, or abnormality of physiological parameters (monitored for patient safety during the exercise).

Effect of pulmonary rehabilitation on respiratory muscle strength
-----------------------------------------------------------------

The CET group and the combined training group demonstrated a significant increase in PI~max~ and PE~max~ when compared with the control group (*P*\<0.05). As shown in [Table 2](#t2-copd-12-2655){ref-type="table"}, the differences in ΔPI~max~ between the control group, CET group, and combined training group (−2.38±0.94 cmH~2~O, 1.32±0.91 cmH~2~O, and 5.20±0.89 cmH~2~O, respectively) were statistically significant (*P*\<0.05). [Table 2](#t2-copd-12-2655){ref-type="table"} also shows a significant increase in inspiratory muscle strength in the combined training group when compared with the other two groups. However, there was no significant differences in ΔPE~max~ between the CET group and the combined training group (*P*\>0.05).

Effects of pulmonary rehabilitation on exercise capacity
--------------------------------------------------------

At baseline, there was no significant difference in exercise capacity between groups. After training, no significant changes of the exercise capacity indices were found in control group. There were significant increases from baseline in the 6MWT, VO~2max~, VO~2max~ %pred, VO~2max~/kg, AT, AT %pred and workload (all *P*\<0.05) in both CET group and combined training group ([Table 3](#t3-copd-12-2655){ref-type="table"}). However, the increases in these indicators did not differ between CET group and combined training group (*P*\>0.05). At the end of 6-minute walking distance test and the measured time points of CPET, the Borg score demonstrated no significant changes in all groups after training. At baseline, there were no differences in VE, VT, Rf, RER, HR, and SPO~2~ between groups. These parameters demonstrated no significant improvement after training in all groups ([Table 3](#t3-copd-12-2655){ref-type="table"}). During CPET, there were no significant differences in these parameters at all time points, as shown in [Figure 1](#f1-copd-12-2655){ref-type="fig"}.

Effects of pulmonary rehabilitation on static pulmonary function
----------------------------------------------------------------

There were no changes in FVC, FVCpred, FEV~1~, FEV~1~pred, FEV~1~/FVC, and MVV (all *P*\>0.05) from baseline in any of the groups after intervention ([Table 2](#t2-copd-12-2655){ref-type="table"}). A significant increase in IC was found in both the CET group and the combined training group. However, there was no difference in ΔIC between CET group and combined training group after intervention (*P*\<0.05).

Effects of pulmonary rehabilitation on dyspnea, quality of life, nutritional status, and depression and anxiety
---------------------------------------------------------------------------------------------------------------

There were no significant differences with regard to BMI or BODE index between groups after training. The CET group and the combined training group demonstrated significant improvements in dyspnea, quality of life, FFMI, and depression and anxiety when compared with the control group (*P*\<0.05). However, there were no significant differences in improvements in these parameters between the CET group and the combined training group after intervention (*P*\>0.05).

Effects of the CET + IMT combination in patients with vs without respiratory muscle weakness
--------------------------------------------------------------------------------------------

We performed a subgroup analysis in patients from the combined training group to determine the effect of combined training on patients with or without respiratory muscle weakness. Thus, we allocated the patients in the combined training group to two subgroups based on their respiratory muscle strength. The respiratory muscle weakness was defined as a PI~max~ \<60 cmH~2~O. At baseline, when subgroup analysis was performed in the combined training group, there were no significant differences in PE~max~, exercise capacity, static pulmonary function, dyspnea, quality of life, depression and anxiety, or nutritional status between patients with and without respiratory muscle weakness. However, these parameters also demonstrated no significant differences between the two subgroups after training (*P*\>0.05; [Table 4](#t4-copd-12-2655){ref-type="table"}). There was no significant differences in ΔPI~max~ between the two subgroups after training (*P*\>0.05; [Table 4](#t4-copd-12-2655){ref-type="table"}).

Effects of pulmonary rehabilitation in patients with vs without malnutrition
----------------------------------------------------------------------------

At baseline, malnutrition was defined as FFMI ≤16 kg/m^2^ in men and ≤15 kg/m^2^ in women. A post hoc analysis on effects of pulmonary rehabilitation in patients with versus without malnutrition was performed, pooling subjects from the CET group and combined training group (n=55, 7 females and 48 males) and reallocating them as subjects with normal nutrition or with malnutrition. There were no significant differences of improvements in respiratory muscle strength, exercise capacity, static pulmonary function, dyspnea, quality of life, depression and anxiety or BMI between two subgroups both before and after training (*P*\>0.05; [Table 5](#t5-copd-12-2655){ref-type="table"}). The ΔFFMI demonstrated no significant differences between patients with normal nutrition and malnutrition after training (*P*\>0.05; [Table 5](#t5-copd-12-2655){ref-type="table"}).

Discussion
==========

The present study demonstrated a significantly greater improvement in inspiratory muscle strength, but not in other measurements including exercise capacity, IC, dyspnea, quality of life, nutritional status, and depression and anxiety, as achieved by CET + IMT compared with CET alone. Furthermore, combined training did not confer an additional benefit in COPD patients with inspiratory muscle weakness when compared with CET alone. While pulmonary rehabilitation could lead to significant improvement in nutritional status of COPD patients, nutritional status did not appear to affect the effects of pulmonary rehabilitation.

Exercise training was shown to improve respiratory muscle strength, exercise capacity, IC, and quality of life, and also relieve dyspnea.[@b29-copd-12-2655],[@b30-copd-12-2655] Lower limb training represents one of the best available means of exercise training.[@b4-copd-12-2655] However, the training effects in some cases are typically modest, given that a few COPD patients have to stop training or lower their training intensity because of dyspnea during exercise.[@b5-copd-12-2655],[@b31-copd-12-2655] Therefore, greater pulmonary rehabilitation effects could potentially be achieved should the severity of dyspnea be reduced. IMT can improve the strength and endurance of the respiratory muscles and decrease dyspnea in COPD patients during their training.[@b5-copd-12-2655] However, our study did not indicate that the addition of IMT enhanced the training effect. The reason could be explained by the fact that IMT did not reduce exercise-related dyspnea as indicated by Larson et al, even though it increased strength of the inspiratory muscles.[@b10-copd-12-2655]

Wanke et al demonstrated that a combination of CET and IMT could significantly improve inspiratory muscle performance, maximal oxygen uptake, and peak ventilatory pattern when compared with CET alone after 8 weeks of training.[@b11-copd-12-2655] Our findings were inconsistent with those results. Possible reasons for the inconsistent findings across previous studies and ours could be explained by several aspects. First, the respiratory muscle exercise used in the study by Wanke et al included endurance and strength exercises, while strength exercise alone was included in our study. Second, in the study by Wanke et al, respiratory muscle exercise consisted of high-intensity pressure loads during exercise, which was performed four times a week. For strength training, their patients had to maintain pressure of at least 80% PI~max~ in each set. For endurance training, the pressure was 70% PI~max~. Strength training was performed first, and followed by endurance training after at least 10 minutes. In contrast, our study design drew from 2013 ATS/ERS statement on pulmonary rehabilitation, whereby IMT was performed at a load of 30% PI~max~ for each patient at the start of training, which was progressively increased if tolerated.[@b4-copd-12-2655] This exercise intensity had been able to benefit both the respiratory muscle strength and endurance. Therefore, we speculated that whether high-intensity IMT as an adjunct to whole-body exercise training may confer additional benefits in pulmonary rehabilitation needs to be validated by further studies.

Dynamic hyperinflation was common in patients with COPD and changes in IC were used in assessing the level of dynamic hyperinflation.[@b32-copd-12-2655],[@b33-copd-12-2655] The present study showed that exercise training could increase IC and improve dynamic hyperinflation. However, we found that the addition of IMT did not offer additional effects in terms of IC. The reason could be that the increased respiratory muscle strength still may not effectively improve the abnormal position of diaphragm due to the long-term dynamic hyperinflation.

COPD is known as a chronic systemic inflammatory disease which could lead to severe respiratory symptoms and meanwhile a series of extrapulmonary manifestations, including peripheral skeletal muscle weakness or atrophy, osteoporosis, malnutrition, and depression. As the first-line non-medication treatment, the effects of pulmonary rehabilitation should be evaluated comprehensively. Most of the current studies on pulmonary rehabilitation focus on individual aspects of treatment effects, such as symptoms, exercise performance, or quality of life. In a study by Nikoletou et al, it was highlighted that multiple tests could provide a more comprehensive assessment of muscle functions.[@b34-copd-12-2655] However, those authors evaluated the effects of IMT alone, without comparison to other rehabilitation programs. The sniff inspiratory nasal pressure, a new and main inspiratory muscle test used in that study, was positively correlated with PI~max~, and was no better than PI~max~ in evaluating respiratory muscle function. In another study, Beaumont et al also attempted to demonstrate the effectiveness of IMT on dyspnea using the Borg scale and multidimensional dyspnea profile questionnaire.[@b35-copd-12-2655] However, in terms of symptom evaluation, they assessed only dyspnea but not other common symptoms in COPD like fatigue, cough, weakness, sleeplessness, and psychological distress. In the present study, several tools (mMRC, CAT, SGRQ, and RPE) were employed for assessment of symptoms. We used PI~max~ for assessing respiratory muscle function, incremental cycle ergometer tests for assessing exercise performance, HADS for assessing depression and anxiety, and FFMI and BMI for assessing nutritional status. These efforts were exerted for a comprehensive approach to evaluate the outcomes of pulmonary rehabilitation. We speculated all these measurements, which were rarely used simultaneously in similar studies on this topic, would add to the reliability of our findings.

Reduced inspiratory muscle strength is one of the factors leading to hypoxemia, hypercapnia, dyspnea, and decreased exercise tolerance.[@b36-copd-12-2655] In patients with COPD, inspiratory muscle dysfunction, along with an impaired length-tension relationship, is one of the main contributors to decreased inspiratory muscle strength.[@b12-copd-12-2655],[@b37-copd-12-2655]--[@b40-copd-12-2655] A study reported by Petrovic et al found that IMT improves performance, exercise capacity, and dyspnea, and increases the inspiratory fraction, which is a prognostic factor in patients with COPD.[@b41-copd-12-2655] A meta-analysis that included 32 randomized controlled trials reporting the effects of IMT in patients with COPD also found that IMT improves inspiratory muscle strength and endurance, functional exercise capacity, dyspnea, and quality of life.[@b8-copd-12-2655]

However, the randomized study by Beaumont et al also concluded that IMT, when used as an adjunct to a 3-week standardized rehabilitation program, was not associated with a significant improvement in either dyspnea or functional parameters in patients with COPD and a PI~max~ \>60 cmH~2~O.[@b35-copd-12-2655] Although the 2013 ATS/ERS statement on pulmonary rehabilitation indicates that combined exercise may bring additional benefits in COPD patients with respiratory muscle weakness,[@b4-copd-12-2655] the results of the present study showed that IMT may not be useful when combined with CET in this subset of patients. This finding could be explained by the fact that high-intensity lower limb training protocol, used in our study, increased muscle strength and endurance directly and improved respiratory muscle function at the same time. In our subjects, the increased oxygen consumption during exercise caused increased activity of the diaphragm and other accessory respiratory muscles. Furthermore, the intensity of the exercise load met the requirements for pulmonary rehabilitation exercise.[@b33-copd-12-2655] A recent study by Chun et al provides strong evidence to support this view.[@b42-copd-12-2655] They used fluoroscopy-guided chest radiography to assess improvements in diaphragmatic movement before and after pulmonary rehabilitation in 117 patients with COPD, and found significantly improved diaphragmatic movement in both lungs after pulmonary rehabilitation. Therefore, in patients with COPD and respiratory muscle weakness, exercise of the lower limbs improves respiratory muscle function. It is difficult to produce further benefits of exercise in pulmonary rehabilitation by adding IMT.

In this study, BMI and FFMI were used to evaluate the changes of nutritional status before and after pulmonary rehabilitation. Our results showed no significant change in BMI after pulmonary rehabilitation, which was consistent with the previous studies. But we also found a great improvement in FFMI. Our previous studies had shown that FFMI was better than BMI in reflecting the nutritional status of patients with COPD.[@b27-copd-12-2655] When patients undergo high-intensity exercise, the body fat was combusted as major energy. Along with the training, the weight of fat may decrease and muscle mass increase. Although there may not be a significant change in BMI after pulmonary rehabilitation, the proportion of fat-free mass could be increasing. Therefore, we speculated that pulmonary rehabilitation training could improve the nutritional status of COPD patients. In addition, our results also showed that there was no significant difference in exercise tolerance and other indicators between patients with and without malnutrition after pulmonary rehabilitation exercise, suggesting that nutritional status may have little impact on rehabilitation training. However, due to the small number of patients with malnutrition included in this study, this could not be conclusive, thus further studies are needed.

One major limitation of our study was the small number of patients with respiratory muscle weakness. Given that only 20%--50% of patients with COPD have respiratory muscle weakness, as reported in previous studies,[@b5-copd-12-2655] it should not be surprising that there were fewer patients with weakened inspiratory muscle strength than those with normal measurement in the present study. Another limitation is the small number of female patients in training. Further trials should expand the sample of female patients to explore the effect of combined training. Despite these, when compared with previous studies, we included more patients participating in training and used newer indicators to comprehensively evaluate the effects of pulmonary rehabilitation. Even though our results revealed that combined CET and IMT did not confer additional effects, we nevertheless provided evidence about the value of IMT combined with general exercise training. Meanwhile, the present study also offered a basis for the comprehensive assessment of pulmonary rehabilitation by using multiple indicators. Besides, the effects of pulmonary rehabilitation compared in patients with different inspiratory muscle strengths and nutritional status would guide physicians in working-up individualized pulmonary rehabilitation programs.

Conclusion
==========

The present study showed that combined training is more effective for increasing inspiratory muscle strength when compared with CET alone, but not for improving exercise performance, IC, dyspnea, depressive symptoms, and nutritional status. However, IMT may not be useful when combined with CET in patients with inspiratory muscle weakness. While COPD patients may experience significant improvements in nutritional status after pulmonary rehabilitation, nutritional status did not appear to have any impact on the outcomes of pulmonary rehabilitation. A comprehensive approach can be more objective to evaluate the effects of combined CET and IMT, and may be more meaningful for individualized pulmonary rehabilitation in the future.
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![Changes of ventilatory pattern, HR, SPO~2~, and Borg scale during CPET.\
**Notes:** Data are presented as mean ± SE unless otherwise stated; Δ, difference (after minus before intervention); *P*-value results of analysis of repeated measures analysis of variance (ANOVA) comparison of the differences between groups.\
**Abbreviations:** CET, cycle ergometer training; IMT, inspiratory muscle training; AT, anaerobic threshold; VE, minute ventilation; Rf, respiratory frequency; VT, tidal volume; SPO~2~, pulse oxygen saturation; HR, heart rate; RER, respiratory exchange ratio; CPET, cardiopulmonary exercise testing.](copd-12-2655Fig1){#f1-copd-12-2655}

![Flow diagram for studies included.\
**Abbreviation:** CET, cycle ergometer training.](copd-12-2655Fig2){#f2-copd-12-2655}
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Patient characteristics at baseline

  -------------------------------------------------------------------------------------------------------
  Parameter                 Control group\   CET group\    Combined training group\   *F*     *P*-value
                            (n=26)           (n=27)        (n=28)                             
  ------------------------- ---------------- ------------- -------------------------- ------- -----------
  Age (years)               69.8±6.4         70.0±6.3      70.8±4.5                   0.237   0.790

  PI~max~ (cmH~2~O)         63.81±23.73      74.66±13.83   72.40±20.41                2.227   0.115

  PE~max~ (cmH~2~O)         64.74±39.09      77.24±30.03   77.40±35.82                1.132   0.327

  6MWD (m)                  525±70           511±77        538±60                     1.101   0.338

  VO~2max~ (mL/min)         1,011±390        1,154±297     994±272                    2.015   0.140

  VO~2max~ %pred (%)        61.83±22.23      66.81±16.64   65.25±15.61                0.492   0.613

  VO~2max~/kg (mL/min/kg)   17.01±6.24       18.13±4.82    17.18±3.94                 0.374   0.689

  AT (mL/min)               823±321          923±197       804±188                    1.912   0.155

  AT%pred (%)               50.75±19.67      53.59±11.62   52.93±11.26                0.266   0.767

  FVC (L)                   2.69±0.70        2.78±0.66     2.41±0.62                  2.276   0.110

  FVC%pred (%)              84.15±20.56      80.89±18.73   75.21±16.19                1.620   0.204

  FEV~1~ (L)                1.42±0.46        1.33±0.47     1.19±0.40                  1.959   0.148

  FEV~1~ %pred (%)          57.54±18.98      51.26±18.00   49.82±16.14                1.429   0.246

  FEV~1~/FVC                53.19±10.18      47.23±9.90    49.60±11.18                2.180   0.120

  MVV (L)                   51.33±17.92      52.65±18.21   46.54±18.75                0.850   0.431

  IC (L)                    1.77±0.52        1.90±0.46     1.71±0.53                  0.994   0.375

  mMRC                      1.19±0.85        1.41±0.84     1.29±0.81                  0.444   0.643

  CAT                       7.96±5.24        8.93±5.21     8.93±5.64                  0.285   0.753

  SGRQ                      12.62±7.40       14.93±8.82    16.14±6.79                 1.446   0.242

  HADS                      5.27±3.26        4.85±2.70     5.50±4.35                  0.239   0.788

  HADS depression           3.00±2.28        2.44±1.72     3.54±3.23                  1.309   0.276

  HADS anxiety              2.27±2.05        2.41±1.28     1.96±1.64                  0.501   0.608

  BMI (kg/m^2^)             21.31±3.78       22.40±2.85    21.31±2.76                 1.071   0.348

  FFMI (kg/m^2^)            16.65±1.92       16.86±1.54    16.24±1.36                 1.075   0.346

  BODE                      1.81±1.36        2.33±1.90     2.46±1.58                  1.211   0.303
  -------------------------------------------------------------------------------------------------------

**Notes:** Data are presented as mean ± SD unless otherwise stated; *P*-value results of analysis of variance (ANOVA) comparison between three groups at baseline.

**Abbreviations:** CET, cycle ergometer training; PI~max~, maximal inspiratory pressure; PE~max~, maximal expiratory pressure; 6MWD, 6-minute walking distance; VO~2max~, maximal oxygen consumption; AT, anaerobic threshold; FVC, forced vital capacity; FEV~1~, forced expiratory volume in 1 second; %pred, percent predicted; MVV, maximal voluntary ventilation; IC, inspiratory capacity; mMRC, modified Medical Research Council; CAT, COPD Assessment Test; SGRQ, St George's Respiratory Questionnaire; HADS, Hospital Anxiety and Depression Scale; BMI, body mass index; FFMI, fat-free mass index; BODE, body mass index, airflow obstruction, dyspnea, and exercise capacity index.

###### 

Effects of pulmonary rehabilitation in the combined training, CET, and control groups

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Parameter            Control group\   CET group\                                               Combined training group\                                                                             *F*      *P*-value
                       (n=26)           (n=27)                                                   (n=28)                                                                                                        
  -------------------- ---------------- -------------------------------------------------------- ---------------------------------------------------------------------------------------------------- -------- -----------
  ΔPI~max~ (cmH~2~O)   −2.38±0.94       1.32±0.91[a](#tfn4-copd-12-2655){ref-type="table-fn"}    5.20±0.89[a](#tfn4-copd-12-2655){ref-type="table-fn"},[b](#tfn5-copd-12-2655){ref-type="table-fn"}   17.151   \<0.001

  ΔPE~max~ (cmH~2~O)   −5.29±1.97       5.42±1.92[a](#tfn4-copd-12-2655){ref-type="table-fn"}    2.37±1.88[a](#tfn4-copd-12-2655){ref-type="table-fn"}                                                7.943    0.001

  ΔFVC (L)             0.00±0.05        −0.02±0.05                                               0.11±0.05                                                                                            2.211    0.117

  ΔFVC%pred (%)        −2.10±2.20       −0.69±2.15                                               4.83±2.13                                                                                            2.832    0.065

  ΔFEV~1~ (L)          −0.02±0.03       0.01±0.03                                                0.06±0.03                                                                                            0.593    0.555

  ΔFEV~1~ %pred (%)    1.75±1.61        0.16±1.56                                                1.23±1.54                                                                                            0.264    0.769

  ΔFEV~1~/FVC          −3.23±2.00       0.55±1.96                                                −0.13±1.90                                                                                           1.007    0.370

  ΔMVV (L)             1.11±1.20        0.90±1.18                                                4.14±1.17                                                                                            2.360    0.101

  ΔIC (L)              −0.04±0.02       0.06±0.02[a](#tfn4-copd-12-2655){ref-type="table-fn"}    0.10±0.02[a](#tfn4-copd-12-2655){ref-type="table-fn"}                                                13.209   \<0.001

  ΔmMRC                0.11±0.13        −0.33±0.13[a](#tfn4-copd-12-2655){ref-type="table-fn"}   −0.47±0.13[a](#tfn4-copd-12-2655){ref-type="table-fn"}                                               5.534    0.006

  ΔCAT                 0.30±0.35        −3.00±0.34[a](#tfn4-copd-12-2655){ref-type="table-fn"}   −2.39±0.34[a](#tfn4-copd-12-2655){ref-type="table-fn"}                                               25.715   \<0.001

  ΔSGRQ                0.95±0.56        −3.51±0.54[a](#tfn4-copd-12-2655){ref-type="table-fn"}   −3.32±0.54[a](#tfn4-copd-12-2655){ref-type="table-fn"}                                               20.598   \<0.001

  ΔHADS                −0.12±0.39       −3.47±0.39[a](#tfn4-copd-12-2655){ref-type="table-fn"}   −3.16±0.38[a](#tfn4-copd-12-2655){ref-type="table-fn"}                                               22.410   \<0.001

  ΔHADS depression     −0.15±0.28       −2.20±0.27[a](#tfn4-copd-12-2655){ref-type="table-fn"}   −2.10±0.27[a](#tfn4-copd-12-2655){ref-type="table-fn"}                                               17.605   \<0.001

  ΔHADS anxiety        −0.10±0.20       −1.32±0.20[a](#tfn4-copd-12-2655){ref-type="table-fn"}   −1.07±0.20[a](#tfn4-copd-12-2655){ref-type="table-fn"}                                               14.470   \<0.001

  ΔBMI (kg/m^2^)       −0.02±0.21       0.54±0.21                                                0.23±0.21                                                                                            1.712    0.187

  ΔFFMI (kg/m^2^)      −0.11±0.24       0.68±0.24[a](#tfn4-copd-12-2655){ref-type="table-fn"}    0.87±0.23[a](#tfn4-copd-12-2655){ref-type="table-fn"}                                                4.825    0.011

  ΔBODE                −0.07±0.13       −0.02±0.12                                               −0.24±0.12                                                                                           1.194    0.309
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:** Data are presented as mean ± SE unless otherwise stated; Δ, difference (after minus before intervention); *P*-value results of analysis of covariance comparison of the differences between groups;

*P*\<0.05 vs control group;

*P*\<0.05 vs CET group.

**Abbreviations:** CET, cycle ergometer training; PI~max~, maximal inspiratory pressure; PE~max~, maximal expiratory pressure; FVC, forced vital capacity; FEV~1~, forced expiratory volume in 1 second; %pred, percent predicted; MVV, maximal voluntary ventilation; IC, inspiratory capacity; mMRC, modified Medical Research Council; CAT, COPD Assessment Test; SGRQ, St George's Respiratory Questionnaire; HADS, Hospital Anxiety and Depression Scale; BMI, body mass index; FFMI, fat-free mass index; BODE, body mass index, airflow obstruction, dyspnea, and exercise capacity index.

###### 

Change in exercise capacity and CPET paraments after pulmonary rehabilitation in the combined training, CET, and control groups

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Parameter                   Control group\   CET group\                                                 Combined training group\                                   *F*      *P*-value
                              (n=26)           (n=27)                                                     (n=28)                                                              
  --------------------------- ---------------- ---------------------------------------------------------- ---------------------------------------------------------- -------- -----------
  6MWD                                                                                                                                                                        

   ΔDistance (m)              −1.64±4.64       32.55±4.59[a](#tfn8-copd-12-2655){ref-type="table-fn"}     21.68±4.51[a](#tfn8-copd-12-2655){ref-type="table-fn"}     14.320   \<0.001

   ΔBorg                      0.35±0.24        −0.10±0.24                                                 −0.23±0.23                                                 1.620    0.205

  Rest CPET variables                                                                                                                                                         

   ΔVE (L/min)                0.14±0.23        0.16±0.23                                                  −0.43±0.22                                                 2.301    0.107

   ΔRf (b/min)                0.05±0.31        −0.21±0.30                                                 −0.69±0.30                                                 1.666    0.196

   ΔVT (L)                    −0.01±0.01       0.01±0.02                                                  −0.01±0.02                                                 0.630    0.535

   ΔRER                       0.01±0.01        0.03±0.01                                                  0.02±0.01                                                  0.746    0.478

   ΔSPO~2~ (%)                0.12±0.13        0.30±0.12                                                  0.31±0.12                                                  0.714    0.493

   ΔHR (b/min)                −1.37±1.56       −2.64±1.53                                                 −4.22±1.49                                                 0.878    0.420

  Peak CPET variables                                                                                                                                                         

   ΔVE (L/min)                0.91±0.92        1.96±0.90                                                  0.20±0.89                                                  0.989    0.377

   ΔRf (b/min)                0.51±0.61        0.50±0.60                                                  −0.60±0.59                                                 1.140    0.325

   ΔVT (L)                    0.01±0.02        0.00±0.02                                                  0.01±0.02                                                  0.057    0.945

   ΔRER                       −0.01±0.01       0.00±0.01                                                  −0.02±0.01                                                 1.089    0.342

   ΔSPO~2~ (%)                0.28±0.44        −0.39±0.43                                                 0.22±0.42                                                  0.743    0.479

   ΔHR (b/min)                −1.96±1.83       0.81±1.79                                                  −1.21±1.76                                                 0.631    0.535

   ΔVO~2max~ (mL/min)         3.45±20.96       149.01±20.04[a](#tfn8-copd-12-2655){ref-type="table-fn"}   122.96±19.47[a](#tfn8-copd-12-2655){ref-type="table-fn"}   14.180   \<0.001

   ΔVO~2max~ %pred (%)        0.34±1.43        9.56±1.35[a](#tfn8-copd-12-2655){ref-type="table-fn"}      6.28±1.32[a](#tfn8-copd-12-2655){ref-type="table-fn"}      11.143   \<0.001

   ΔVO~2max~/kg (mL/min/kg)   −0.58±0.39       2.56±0.36[a](#tfn8-copd-12-2655){ref-type="table-fn"}      2.26±0.36[a](#tfn8-copd-12-2655){ref-type="table-fn"}      21.037   \<0.001

   ΔAT (mL/min)               −0.29±34.72      157.53±33.19[a](#tfn8-copd-12-2655){ref-type="table-fn"}   104.75±32.30[a](#tfn8-copd-12-2655){ref-type="table-fn"}   5.482    0.006

   ΔAT%pred (%)               −0.27±1.96       7.68±1.84[a](#tfn8-copd-12-2655){ref-type="table-fn"}      4.90±1.81[a](#tfn8-copd-12-2655){ref-type="table-fn"}      4.453    0.015

   ΔPower (Watt)              −0.62±2.29       11.86±2.25[a](#tfn8-copd-12-2655){ref-type="table-fn"}     6.10±2.21[a](#tfn8-copd-12-2655){ref-type="table-fn"}      7.547    0.001

   ΔBorg                      0.08±0.20        −0.18±0.20                                                 −0.36±0.20                                                 1.258    0.290
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:** Data are presented as mean ± SE unless otherwise stated; Δ, difference (after minus before intervention); *P*-value results of analysis of covariance comparison of the differences between groups;

*P*\<0.05 vs control group.

**Abbreviations:** CET, cycle ergometer training; CPET, cardiopulmonary exercise testing; 6MWD, 6-minute walking distance; VE, minute ventilation; Rf, respiratory frequency; VT, tidal volume; RER, respiratory exchange ratio; SPO~2~, pulse oxygen saturation; HR, heart rate; VO~2max~, maximal oxygen consumption; %pred, percent predicted; AT, anaerobic threshold.

###### 

Effects of combined training in patients who had COPD with or without respiratory muscle weakness

  ----------------------------------------------------------------------------------------------------------------------
  Parameter                  Normal respiratory muscle group\   Weakened respiratory muscle group\   *F*     *P*-value
                             (n=19)                             (n=9)                                        
  -------------------------- ---------------------------------- ------------------------------------ ------- -----------
  ΔPI~max~ (cmH~2~O)         6.89±1.45                          1.22±2.44                            2.980   0.097

  ΔPE~max~ (cmH~2~O)         0.46±1.69                          4.03±2.52                            1.308   0.264

  Δ6MWT (m)                  16.67±6.70                         28.14±10.70                          0.673   0.420

  ΔVO~2~max (mL/min)         137.93±24.76                       78.60±37.13                          1.642   0.212

  ΔVO~2~max%pred (%)         6.65±1.95                          5.63±2.97                            0.073   0.790

  ΔVO~2~max/kg (mL/min/kg)   2.32±0.34                          2.08±0.50                            0.154   0.698

  ΔAT (mL/min)               102.50±38.09                       96.72±57.39                          0.006   0.937

  ΔAT%pred (%)               5.38±2.58                          3.87±3.95                            0.091   0.766

  ΔFVC (L)                   0.12±0.08                          0.10±0.12                            0.018   0.985

  ΔFVC%pred (%)              6.71±3.41                          2.95±4.99                            0.380   0.543

  ΔFEV~1~ (L)                0.02±0.06                          0.15±0.08                            1.789   0.193

  ΔFEV~1~ %pred (%)          0.01±2.64                          4.66±3.87                            0.966   0.335

  ΔFEV~1~/FVC                0.51±1.23                          0.90±1.81                            0.403   0.531

  ΔMVV (L)                   2.55±1.94                          7.72±2.83                            2.244   0.147

  ΔIC (L)                    0.10±0.03                          0.13±0.04                            0.305   0.586

  ΔmMRC                      −0.53±0.17                         −0.33±0.25                           0.361   0.553

  ΔCAT                       −2.45±0.32                         −2.38±0.48                           0.016   0.899

  ΔSGRQ                      −3.19±0.74                         −4.26±1.15                           0.520   0.478

  ΔHADS                      −2.88±0.40                         −4.25±0.60                           3.320   0.080

  ΔHADS depression           −2.07±0.35                         −3.19±0.52                           3.046   0.093

  ΔHADS anxiety              −0.94±0.12                         −1.01±0.18                           0.093   0.762

  ΔBMI (kg/m^2^)             0.49±0.30                          −0.25±0.43                           1.980   0.172

  ΔFFMI (kg/m^2^)            1.28±0.37                          0.27±0.55                            2.240   0.147

  ΔBODE                      −0.20±0.22                         −0.47±0.34                           0.410   0.528
  ----------------------------------------------------------------------------------------------------------------------

**Notes:** Data are presented as mean ± SE unless otherwise stated; Δ, difference (after minus before intervention); *P*-value results of analysis of covariance comparison of the differences between groups.

**Abbreviations:** PI~max~, maximal inspiratory pressure; PE~max~, maximal expiratory pressure; 6MWD, 6-minute walking distance; VO~2max~, maximal oxygen consumption; AT, anaerobic threshold; FVC, forced vital capacity; FEV~1~, forced expiratory volume in 1 second; %pred, percent predicted; MVV, maximal voluntary ventilation; IC, inspiratory capacity; mMRC, modified Medical Research Council; CAT, COPD Assessment Test; SGRQ, St George's Respiratory Questionnaire; HADS, Hospital Anxiety and Depression Scale; BMI, body mass index; FFMI, fat-free mass index; BODE, body mass index, airflow obstruction, dyspnea, and exercise capacity index.

###### 

Effects of pulmonary rehabilitation in COPD patients with malnutrition

  ------------------------------------------------------------------------------------------------
  Parameter                  Normal nutrition group\   Malnutrition group\   *F*       *P*-value
                             (n=43)                    (n=12)                          
  -------------------------- ------------------------- --------------------- --------- -----------
  ΔPI~max~ (mmH~2~O)         3.17±0.90                 1.78±1.73             0.039     0.844

  ΔPE~max~ (mmH~2~O)         4.25±1.79                 −0.95±3.39            1.847     0.180

  Δ6MWT (m)                  27.84±4.21                24.01±8.02            0.177     0.675

  ΔVO~2max~ (mL/min)         125.91±17.34              176.91±34.03          1.711     0.197

  ΔVO~2max~ %pred (%)        7.52±1.24                 9.72±2.38             0.656     0.422

  ΔVO~2max~/kg (mL/min/kg)   2.38±0.28                 2.56±0.53             0.097     0.757

  ΔAT (mL/min)               125.65±31.76              153.51±65.37          0.134     0.716

  ΔAT%pred (%)               6.59±1.79                 5.07±3.57             0.136     0.714

  ΔFVC (L)                   0.04±0.05                 0.06±0.09             0.042     0.838

  ΔFVC%pred (%)              2.73±1.78                 1.21±3.4              0.156     0.694

  ΔFEV~1~ (L)                0.03±0.03                 0.07±0.06             0.306     0.582

  ΔFEV~1~ %pred (%)          0.76±1.35                 1.43±2.56             0.054     0.818

  ΔFEV~1~/FVC                0.86±0.73                 −0.75±1.39            1.054     0.309

  ΔMVV (L)                   2.51±1.13                 2.76±2.16             0.01      0.919

  ΔIC (L)                    0.02±0.02                 −0.03±0.03            1.844     0.180

  ΔmMRC                      −0.43±0.10                −0.38±0.19            0.046     0.832

  ΔCAT                       −2.87±0.25                −2.20±0.47            1.587     0.213

  ΔSGRQ                      −3.58±0.41                −3.43±0.78            0.026     0.872

  ΔHADS                      −3.18±0.27                −3.18±0.54            \<0.001   0.989

  ΔHADS depression           −2.03±0.23                −2.99±0.47            3.228     0.078

  ΔHADS anxiety              −1.19±0.12                −0.92±0.23            1.015     0.318

  ΔBMI (kg/m^2^)             0.37±0.21                 0.36±0.42             0.001     0.981

  ΔFFMI (kg/m^2^)            0.76±0.25                 0.86±0.59             0.020     0.889

  ΔBODE                      −0.16±0.12                −0.10±0.23            0.049     0.825
  ------------------------------------------------------------------------------------------------

**Notes:** Data are presented as mean ± SE unless otherwise stated; Δ, difference (after minus before intervention); *P*-value results of analysis of covariance comparison of the differences between groups.

**Abbreviations:** PI~max~, maximal inspiratory pressure; PE~max~, maximal expiratory pressure; 6MWD, 6-minute walking distance; VO~2max~, maximal oxygen consumption; AT, anaerobic threshold; FVC, forced vital capacity; FEV~1~, forced expiratory volume in 1 second; %pred, percent predicted; MVV, maximal voluntary ventilation; IC, inspiratory capacity; mMRC, modified Medical Research Council; CAT, COPD Assessment Test; SGRQ, St George's Respiratory Questionnaire; HADS, Hospital Anxiety and Depression Scale; BMI, body mass index; FFMI, fat-free mass index; BODE, body mass index, airflow obstruction, dyspnea, and exercise capacity index.
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